J&J, Medivir get EU nod for their hep C drug Olysio

Save

The horse race for oral treatments of chronic hepatitis C entered another turn today as the European Union recommended approval of Olysio, the Johnson & Johnson and Medivir entry in the high-stakes derby, Bloomberg reports.